Study identifier:NIS-GES-DUM-2008/2
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Compliance of gastroprotection treatment in the prevention of Gastrointestinal risk in Non-Steroidal anti-inflammatory drug (NSAID) using patients
Compliance
-
No
-
All
2000
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
Prospective multicentric study to evaluate the compliance of gastroprotective treatment in NSAID patients at risk of GI complications. Secondary objectives: To identify the factors associated to treatment compliance (both NSAID and PPI), to evaluate the relationship between compliance and NSAID-associated GI events
Location
Location
A CORU�A, La Coru�a, Spain
Location
ALACANT / ALICANTE, Alicante, Spain
Location
ALBACETE, Albacete, Spain
Location
ALCALA DE HENARES, Madrid, Spain
Location
ALCOY, Alicante, Spain
Location
ALGECIRAS, Cadiz, Spain
Location
ALGEMESI, Valencia, Spain
Location
ALMERIA, Almeria, Spain
Arms | Assigned Interventions |
---|---|
1 NSAID patients with risk factors treated with gastroprotective drugs | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.